ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Recent advances and future challenges using biomarkers in oncology precision medicine
Dr. Brian Huber outlines the role biomarkers play in guiding therapeutic strategies.
Why ITT analysis is not always the answer for estimating treatment effects in clinical trials
Dr. Alan Phillips provides his insights on the role of estimands in clinical research.
Clinical Research: One of Ireland's most promising industries
ICON CEO Dr. Steve Cutler discusses clinical research as one of Ireland’s most promising industries in this special supplement on Ireland’s economy that appeared in the weekend edition of the New York Times.
The bottom line: Clinical trials
Nuala Murphy, President Global Specialty Solutions, contributes to the Bottom Line BBC4 podcast about the impact of the COVID-19 vaccine on the clinical trial process and whether these changes could work for other drugs.
Overcoming data flow challenges in cell therapy trials
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this Q&A with ICON expert Olivier Saulin.
Innovation in clinical trial methodologies
In this podcast, Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
Lessons from the first generation of cell and gene oncology trials
ICON’s Tamie Joeckel and Brandon Fletcher take us through best practice approaches to CGT studies and discuss what the future could hold for this exciting area.
Ensuring better patient outcomes through decentralised & hybrid trials
ICON CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster.
Practical considerations when deploying a decentralised or hybrid clinical trial
A discussion around the key components of decentralised trials and steps of deployment.